Association between Toxoplasma gondii seropositivity and Alzheimer’s disease: a case-control study Authors: Maryam Aldaghi, Ali Alizadeh Khatir, Mahdi Sepidarkish, Delaram Arjmandi, Faribourz Mousavi, Saeed Aghapour, Masomeh Bayani, Ali Rostami Published: 2026 ABSTRACT AbstractAlzheimer’s disease (AD) is a progressive neurodegenerative condition marked by declining cognitive function and memory deterioration. Emerging evidence suggests that infectious agents, including Toxoplasma gondii, may contribute to the risk of developing this disorder. Because previous studies on this association have produced limited and inconsistent results, we examined the link between T. gondii infection and Alzheimer’s disease. This case-control study included 90 recently diagnosed AD patients from Ayatollah Rouhani Hospital and Clinic in Babol, Iran, and 91 healthy individuals as controls. After obtaining written informed consent, serum samples were collected from both groups. AD was determined through expert clinical evaluation, and the Mini-Mental State Examination (MMSE) was used to assess cognitive status and disease severity. Anti-T. gondii IgG antibodies were detected using ELISA. Data were analyzed in SPSS using chi-square tests, and odds ratios with 95% confidence intervals were calculated. The seroprevalence of T. gondii was 77.7% in cases and 89.0% in healthy controls. T. gondii seropositivity showed a significant inverse association with AD in both univariate analysis (OR: 0.43, 95% CI: 0.18–0.98; P = 0.04) and multivariate analysis (OR: 0.35, 95% CI: 0.14–0.92; P = 0.03). Additionally, T. gondii seropositivity was significantly associated with lower odds of greater AD severity in multivariate analysis (OR: 0.44, 95% CI: 0.20–0.97; P = 0.04). Our findings suggest an inverse association between T. gondii seropositivity and AD. Moreover, seropositivity was associated with lower odds of more severe disease. Further research is warranted to clarify the biological basis and clinical significance of this association.Keywords: Alzheimer’s disease, Toxoplasma gondii, Toxoplasmosis, ELISA, IgG Introduction Dementia is a neurodegenerative disease affecting approximately 44 million individuals worldwide, with projections reaching 131.5 million by 2050 (Bouscaren et al. 2018; Cummings et al. 2016; Winblad et al. 2016). Accounting for approximately 60–80% of dementia cases, Alzheimer’s disease (AD) is a progressive and incurable neurodegenerative disorder characterized by cognitive decline, functional impairment, loss of independence, and behavioral disturbances (Alzheimer’s Association Report 2020; Lyketsos et al. 2011). AD is a progressive, incurable neurological disease causing cognitive and functional deficits, loss of independence, and behavioral changes. The primary cognitive symptoms include deficits in short-term memory, praxis, and visual-spatial function (Atri 2019). Advancing age is the main risk factor for Alzheimer’s disease, and studies indicate that the risk of developing AD approximately doubles every five years after the age of 65 (Qiu et al. 2009). AD manifests in two forms: early-onset familial AD linked to specific genetic mutations, and the more common late-onset form influenced by multiple factors including potentially infectious agents (Chacko et al. 2022). A range of biological processes has been implicated in the development of Alzheimer’s disease, including disturbances in cholinergic neurotransmission, amyloid-β–related toxicity, abnormal tau phosphorylation, synaptic degeneration, oxidative damage, and neuroinflammation (Briggs et al. 2017; Calsolaro and Edison 2016; Ferreira-Vieira et al. 2016; Kumar and Singh 2015; Lewis and Dickson 2016; Selkoe and Hardy 2016). Neuroinflammation is particularly significant, as it contributes to neuronal degeneration through inflammatory mediators that damage nerve cells and amplify amyloid precursor protein processing (Brown and Bal-Price 2003; Fernández-Vizarra et al. 2004; Heneka and O’Banion 2007; Johnston et al. 2011; Lee et al. 2010). Risk factors for developing Alzheimer’s disease include advanced age, accumulation of amyloid-beta and tau proteins, genetics (e.g., mutations in presenilin-1 and apolipoprotein E [APOE] genes), family history, cardiovascular risk factors, and exposure to various infectious agents including viruses, fungi, bacteria, and parasites (Bekris et al. 2010; de Bruijn and Ikram 2014; Souza et al. 2018). Moreover, growing evidence suggests that AD can be exacerbated by persistent systemic inflammation and various infectious agents (Cunningham 2013; Harris and Harris 2015; Holmes 2013; Jurgens et al. 2012; Krstic et al. 2012; McManus et al. 2014). Some researchers have proposed that specific pathogens, including Helicobacter pylori, Chlamydia pneumoniae, Borrelia burgdorferi, spirochetes, cytomegalovirus (CMV), herpes simplex virus type 1 (HSV-1), and some neurotropic parasites (e.g. Toxoplasma gondii and Toxocara spp.) may play causative roles in AD development (Bu et al. 2015; Carter 2011; Miklossy 2011; Shima et al. 2010). The elderly population, most affected by sporadic AD, is also more susceptible to infections, including latent ones such as toxoplasmosis (Colugnati et al. 2007; Gavazzi and Krause 2002; Montoya and Liesenfeld 2004; Pinchinat et al. 2013). Toxoplasma gondii is a protozoan parasite with a predilection for neural tissue and is estimated to infect about one-third of people worldwide (Dubey 1998). This organism can infect any nucleated cell in a wide range of warm-blooded animals, which serve as intermediate hosts. Transmitted through ingestion of contaminated food, water, or undercooked meat, as well as through blood transfusion, organ transplantation, or congenital routes, T. gondii can remain asymptomatic in immunocompetent individuals, although clinical manifestations such as encephalitis, chorioretinitis, and pneumonitis can arise in those with compromised immunity (Gohardehi et al. 2018; Jones and Dubey 2010; Lee 2000; Nayeri et al. 2021). The parasite demonstrates tropism for brain regions critical to cognitive functions impaired in AD, including the amygdala, frontal cortex, and hippocampus (Berenreiterová et al. 2011; da Silva and Langoni 2009; McConkey et al. 2013). The link between T. gondii infection and Alzheimer’s disease is still debated (Ortiz-Guerrero et al. 2020a). Kusbeci et al. observed higher anti-T. gondii IgG antibody levels among individuals with AD than among controls, whereas Perry et al. reported no significant between-group difference (Kusbeci et al. 2011; Perry et al. 2016a). Interestingly, murine model research by Jung et al. demonstrated that T. gondii infection decreased amyloid-beta plaque formation, suggesting a complex relationship that may differ between species (Jung et al. 2012b). These conflicting findings highlight the need for further investigation into the potential association between T. gondii infection and AD. Methods Study design and population A matched case-control study was carried out between June 2021 and March 2023 at Rouhani Hospital, a referral center in Mazandaran Province in northern Iran. Ethical approval was obtained from the university’s Research Ethics Committee, and written informed consent was secured from all participants or, when necessary, from their legal guardians. The case group included individuals older than 50 years who were referred to the neurology outpatient clinic of Rouhani Hospital. AD was diagnosed by an experienced neurologist based on clinical evaluation, cognitive assessment, and supportive neuroimaging and laboratory findings. These investigations were also used to exclude alternative causes of cognitive impairment. Cognitive performance was evaluated using the Mini-Mental State Examination (MMSE) (Folstein et al. 1983), which was applied to measure overall cognitive function and to categorize disease severity. The MMSE is a 30-point cognitive screening instrument that evaluates several cognitive domains, including orientation, attention, memory, language, and visuoconstructional ability, with lower scores indicating greater impairment (Rajji et al. 2009). In this study, MMSE scores of 21–26 were classified as mild AD, 15–20 as moderate AD, 10–14 as moderately severe AD, and scores below 10 as severe AD (Kompoliti and Verhagen 2010). For regression analyses, severity categories were further collapsed into mild versus moderate-to-severe AD. The participant selection process is illustrated in Fig. 1. Flow chart depicting the selection process of participants in this case-control study To rule out alternative causes of cognitive impairment, neuroimaging and complementary diagnostic evaluations were performed. Individuals with Parkinson’s disease, head trauma, substance abuse, schizophrenia, depression, epilepsy, prior brain surgery, acute encephalitis or meningitis, immunodeficiency disorders, or malignancy were excluded. To reduce the possibility of reverse causation, only patients who had received an AD diagnosis within the previous six months were enrolled. The control group consisted of age- and sex-matched individuals recruited from the General Health Outpatient Clinic of Rouhani Hospital who had no history of AD or other cognitive disorders, as confirmed by expert neurologic evaluation. Some healthy controls reported a family history of AD or other related cognitive disorders (Table 1). Table 1Demographic characteristics of participants based on risk factors for Toxoplasma gondiiVariablePatients with Alzheimer’s disease (n = 90)Healthy controls (n = 91)OR crude (95%CI)p-valueNumber (%)Number (%)Sex Male41 (45.6)49 (53.8)Ref Female49 (54.4)42 (46.2)1.39 (0.77, 2.51)0.265Age ≤ 609 (10)13 (14.3)Ref > 6181 (90)78 (85.7)1.51 (0.61, 3.71)0.380Residence Urban41 (45.6)42 (46.2)Ref Rural49 (54.4)49 (53.8)1.02 (0.57, 1.83)0.936Education Illiterate54 (60)33 (36.3)Reference Primary school27 (30)29 (31.9)0.56 (0.28, 1.12)0.104 High School7 (7.8)21 (23.1)0.20 (0.07, 0.53)0.001 College and above2 (2.2)8 (8.8)0.15 (0.03, 0.76)0.022Occupation Housewife46 (51.1)39 (42.9)Reference Farmer26 (28.9)24 (26.4)0.91 (0.45, 1.84)0.812 Other18 (20)28 (30.8)0.54 (0.26, 1.13)0.103Dog contact No81 (90)80 (87.9)Ref Yes9 (10)11 (12.1)0.80 (0.31, 2.05)0.655Cat contact No85 (94.4)89 (97.8)Ref Yes5 (5.6)2 (2.2)2.61 (0.49, 13.85)0.258Frequent contact with soil No43 (47.8)33 (36.3)Ref Yes47 (52.2)58 (63.7)0.62 (0.34, 1.12)0.118Eating unwashed vegetables No36 (40)25 (27.5)Ref Yes54 (60)66 (72.5)0.56 (0.30, 1.06)0.076Eating raw or undercooked meat No54 (60)33 (36.3)Ref Yes27 (30)29 (31.9)1.53 (0.66, 3.51)0.314Water source Treated73 (81.1)78 (85.7)Ref Untreated17 (18.9)13 (14.3)1.39 (0.63, 3.07)0.406 Demographic characteristics of participants based on risk factors for Toxoplasma gondii Covariates Based on prior literature, a range of variables with possible relevance to cognitive impairment were evaluated as covariates. These comprised demographic, behavioral, and clinical factors, including age, sex, educational attainment, smoking status, thyroid disorder, diabetes, coronary heart disease, systolic blood pressure, regular physical activity, alcohol consumption, and family history of AD and related dementias. Education was grouped into three categories: below high school, high school graduate, and college level or higher. Smoking status was classified as never, former, or current, whereas alcohol use was dichotomized as never versus any use. In addition, variables considered relevant to T. gondii exposure were included in the analysis. These exposure-related factors comprised contact with dogs, cats, or soil, intake of raw vegetables or undercooked meat, and drinking water source, classified as filtered or unfiltered. Sample collection and laboratory analysis Peripheral venous blood was collected from all participants, and serum was separated immediately by centrifugation at 3500 rpm for 5 min. Serum samples were aliquoted, transported to the laboratory on ice, and stored at − 20 °C pending analysis. To minimize measurement bias, laboratory staff were blinded to participant group assignment. Specific serum IgG antibodies against T. gondii were measured using a commercial enzyme-linked immunosorbent assay kit (ACON, USA), which has a reported sensitivity and specificity of more than 95%. Results were expressed in international units, with values < 9.0 IU/mL considered negative, 9.0–11.0 IU/mL considered equivocal, and > 11.0 IU/mL considered positive. In addition to binary serostatus, sample optical density (OD) values were retained and analyzed as a continuous measure of anti-T. gondii IgG serointensity. Anti-T. gondii IgM was not measured because the study was designed to evaluate prior/chronic exposure to T. gondii, rather than acute toxoplasmosis, in relation to Alzheimer’s disease. Statistical analysis All statistical analyses were performed using SPSS software version 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables were summarized as means and standard deviations, whereas categorical variables were presented as frequencies and percentages. Because IgG concentrations were not normally distributed, anti-T. gondii IgG serointensity was summarized as median and interquartile range and compared between groups using the Mann–Whitney U test. Differences between groups were examined using Pearson’s chi-square test or Fisher’s exact test, as appropriate. The seroprevalence of T. gondii infection in cases and controls was reported as percentages with corresponding binomial 95% confidence intervals. Binary logistic regression was performed to estimate crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for the association between T. gondii seropositivity and AD. In addition, for severity analysis, AD severity was dichotomized as mild versus moderate-to-severe, and binary logistic regression was used to assess its association with T. gondii seropositivity. Adjusted models included age, residence, education, smoking, alcohol use, diabetes, cardiovascular disease, water source, physical activity, and family history of AD. Adjusted model fit was assessed using the Hosmer–Lemeshow goodness-of-fit test. A p-value of less than 0.05 was considered statistically significant. Results The study included 90 participants diagnosed with AD and 91 control participants without dementia. Among AD patients, 54.4% were female, compared to 46.2% in the control group. The mean age was 72.16 ± 9.38 years for AD patients and 71.12 ± 10.52 years for healthy controls. Tables 1 and 2 summarize the baseline characteristics of both groups. No statistically significant differences were observed between the groups regarding sex, age, or residence location. Notably, approximately 60% of AD patients had little or no formal education. Regarding comorbidities among AD patients, hypertension was the most prevalent (58.9%), followed by coronary heart disease (43.3%), diabetes (35.6%), and regular exercise habits (31.1%). Additionally, 25.6% were current smokers, 12.2% had thyroid disorders, and 3.3% reported a history of alcohol use disorder. Family history of Alzheimer’s or other cognitive impairment disorders was reported in 34.4% of AD patients compared to 28.6% in the control group. Among the 90 patients with AD, 52 were classified as having mild disease, whereas 38 were categorized as moderate-to-severe disease for severity analysis. Table 2Demographic characteristics of participants based on risk factors for Alzheimer’s diseaseVariablePatients with Alzheimer’s disease (n = 90)Healthy controls (n = 91)OR crude (95%CI)p-valueNumber (%)Number (%)HTN No37 (41.1)41 (45.1)Ref Yes53 (58.9)50 (54.9)1.17 (0.65, 2.11)0.592Diabetes No58 (64.4)69 (75.8)Ref Yes32 (35.6)22 (24.2)1.73 (0.91, 3.29)0.096Smoking No67 (74.4)77 (84.6)Ref Yes23 (25.6)14 (15.4)1.88 (0.91, 3.96)0.093Cardiac disorders No51 (56.7)52 (57.1)Ref Yes39 (43.3)39 (42.9)1.01 (0.56, 1.83)0.948Thyroid disorders No79 (87.8)83 (91.2)Ref Yes11 (12.2)8 (8.8)1.44 (0.55, 3.77)0.453Alcohol use No87 (96.7)84 (92.3)Ref Yes3 (3.3)7 (7.7)0.41 (0.11, 1.65)0.212Family history of Alzheimer’s disease No59 (65.6)65 (71.4)Ref Yes31 (34.4)26 (28.6)1.31 (0.71, 2.46)0.396Regular physical activity No62 (68.9)73 (80.2)Ref Yes28 (31.1)18 (19.8)1.83 (0.92, 3.62)0.082 Demographic characteristics of participants based on risk factors for Alzheimer’s disease Overall anti-T. gondii IgG seropositivity was high among study participants (83.4%). However, seropositivity rates differed between groups, with 77.8% (95% CI, 67.7–85.8%; 70/90) in AD cases compared to 89.0% (95% CI, 80.7–94.6%; 81/91) in the dementia-free control group (Table 3). Univariable analysis revealed a significant inverse association between anti-T. gondii seropositivity and AD diagnosis (OR 0.43, 95% CI 0.18–0.98, P = 0.04). This association remained significant after adjusting for covariates in the multivariable analysis (OR 0.35, 95% CI 0.14–0.92, p = 0.03). When examining AD severity, patients with moderate to severe AD demonstrated lower anti-T. gondii seropositivity (76.3% vs. 78.8%) compared to those with mild AD. Multivariate adjusted analyses showed a statistically significant inverse association between anti-T. gondii seropositivity and greater AD severity (OR 0.44, 95% CI 0.20–0.97, P = 0.04) (Table 3). Anti-T. gondii IgG serointensity, expressed as OD, was also compared between groups. The median OD value was 2.025 (IQR, 1.205–2.544) among AD cases and 3.186 (IQR, 2.117–3.582) among controls, with a statistically significant difference between groups (Mann–Whitney U test, P < 0.001). Table 3Univariate and multivariate analyses to assess whether there is an association between Alzheimer’s and T. gondii seropositivityStudy participantsToxoplasma seropositiveNumber (%)Toxoplasma seronegativeNumber (%)Univariate analysesORs (95% CIs)Multivariate analysesORs (95% CIs) *Hosmer and Lemeshow test – adjusted modelTotal patients with Alzheimer’s disease70 (77.8)20 (22.2)0.43 (0.18, 0.98)0.35 (0.14, 0.92)Pearson chi2 = 254.35, p < 0.001Healthy controls81 (89)10 (11)RefRefMild Alzheimer’s disease41 (78.8)11 (21.2)RefRefPearson chi2 = 368.42, p < 0.001Moderate to severe Alzheimer’s disease29 (76.3)9 (23.7)0.50 (0.25, 1.02)0.44 (0.20, 0.97)*Adjusted model for age, residence, education, smoking, alcohol, diabetes, CVD, water source, physical activity, and family history of Alzheimer Univariate and multivariate analyses to assess whether there is an association between Alzheimer’s and T. gondii seropositivity *Adjusted model for age, residence, education, smoking, alcohol, diabetes, CVD, water source, physical activity, and family history of Alzheimer Discussion In this case-control study conducted in Mazandaran Province, Iran, we observed an inverse association between T. gondii IgG seropositivity and AD. Seropositive individuals had lower odds of AD and lower odds of greater disease severity. After adjustment for potential confounders, T. gondii seropositivity remained associated with lower odds of AD diagnosis and more severe disease categories. These findings should be interpreted as associative rather than causal, given the observational design of the study. Our results contrast with several studies reporting T. gondii as a potential AD risk factor. For instance, Al-Shabani et al. and Mahami-Oskouei et al. observed higher T. gondii seroprevalence in AD patients (Al-Shabani and AL-Waaly 2022; Mahami-Oskouei et al. 2016), with odds ratios of 7.87 and 1.53, respectively. Conversely, Perry et al. (Perry et al. 2016b) and Rashno et al. (Rashno et al. 2016), found no significant association, aligning with our null hypothesis for disease development but not our protective findings. Meta-analyses further highlight this inconsistency, with Bayani et al. reporting no association (OR: 1.39) and Nayeri et al. suggesting a modest risk (OR: 1.53) (Bayani et al. 2019; Chegeni et al. 2019). Differences in geographical location, prevalent T. gondii strains, immune status of the population, and methodological variations (e.g., diagnostic criteria, control selection) may explain these discrepancies. Consistent with this concept, a recent matched case-control study from Colombia reported an inverse association between T. gondii IgG seropositivity and schizophrenia, with a predominance of GRA6-III serotype among IgG-positive participants (Cano et al. 2026). Although schizophrenia and AD are distinct disorders, these findings support the broader possibility that the relationship between T. gondii exposure and brain-related diseases may be heterogeneous and influenced by geographic variation in parasite strain or serotype distribution. Experimental evidence also suggests that this relationship may be biologically complex: Jung et al. demonstrated reduced amyloid-beta (Aβ) plaque formation in T. gondii-infected mice, supporting the plausibility of the inverse association observed in the present study (Jung et al. 2012a). Similarly, Cabral et al. observed strain-specific protection, with hypovirulent type II strains (e.g., ME49) reducing Aβ deposition by > 60% in AD models (Cabral et al. 2017). Our study was conducted in northern Iran, where previous regional reports have suggested a predominance of type II T. gondii strains (Haghparast-Kenari et al. 2020). If this strain distribution applies to our study population, it may partly contribute to the observed inverse association. However, because parasite genotyping was not performed, this explanation remains speculative. The biological plausibility of an inverse association between T. gondii seropositivity and AD is supported by emerging data on the immunomodulatory effects of chronic infection, particularly with hypovirulent strains. Type II strains, common in our study region, are known to elicit a balanced immune response—potent early Th1 activation followed by anti-inflammatory regulation—characterized by elevated levels of IL-10 and TGF-β (Jung et al. 2012a; Ortiz-Guerrero et al. 2020b; Xiao et al. 2022). These cytokines are neuroprotective and may mitigate amyloid-beta deposition and tau hyperphosphorylation, hallmarks of AD pathology (Xiao et al. 2022). Moreover, chronic infection with hypovirulent T. gondii strains has been shown in animal models to reduce AD-like pathology and cognitive impairment (Galeh et al. 2023; Shin et al. 2021). These strains induce sustained immune activation without causing overt neurodegeneration, potentially priming the immune system to clear amyloid aggregates and regulate inflammatory responses. In contrast, virulent strains suppress pro-inflammatory cytokines and may exacerbate CNS damage if the immune response is impaired (Xiao et al. 2022). The presence of tissue cysts, particularly in the hippocampus and cortex, is a feature of chronic T. gondii infection. While historically considered inert, these cysts may actively modulate the brain’s immune milieu, influencing the progression of neurodegenerative diseases. Importantly, MAG1—a cyst-specific antigen—has been correlated with cyst burden and associated with neuroprotective immune activation in murine studies (Parmley et al. 2002; Tomita et al. 2021). Several limitations of our study should be acknowledged. First, although ELISA-based detection of anti-T. gondii IgG provides evidence of prior exposure and allowed assessment of IgG serointensity, it does not differentiate between resolved and persistent infections, nor does it measure brain cyst burden. In addition, anti-T. gondii IgM was not assessed; therefore, acute infection could not be serologically excluded. However, Alzheimer’s disease is a chronic neurodegenerative disorder, and the present study was designed to evaluate prior/chronic T. gondii exposure rather than acute toxoplasmosis. Second, residual confounding cannot be entirely excluded, despite adjustment for multiple covariates. Third, our findings are based on a relatively small, geographically localized population, which may limit generalizability. Fourth, the cross-sectional nature of our case-control design precludes conclusions about causality or temporal relationships. Finally, we did not perform parasite genotyping and therefore could not determine the infecting strain in our participants. Although previous regional studies have suggested a predominance of type II strains, extrapolating those findings to our study population should be done with caution. Conclusion In summary, chronic T. gondii seropositivity was inversely associated with Alzheimer’s disease and greater disease severity in this study population. These findings should be interpreted with caution because the case-control design does not allow causal inference. The results highlight the complexity of the relationship between chronic toxoplasmosis and neurodegenerative disease and underscore the need for further studies exploring strain-specific effects and underlying immunological mechanisms. Future research incorporating molecular strain typing, longitudinal designs, and measures of brain cyst burden (e.g., MAG1 serology or neuroimaging biomarkers) will be important to clarify this association and determine its biological and clinical relevance. Acknowledgements The authors are very thankful to the staff of the Ayatollah Rohani Hospital, Babol, Iran. The authors would also like to thank all the participants in this study. Authors’ contributions Conceptualization, M.A., A.A., and A.R.; methodology and laboratory analysis, M.A., F.M., M.B., S.A., and D.A.; statistical analysis, M.S.; writing—original draft preparation, M.A., A.A.K., and A.R.; writing—review and editing, M.A., M.B, M.S., A.A.K., and A.R.; supervision and funding acquisition, A.R. All authors have read and agreed to the final version of the manuscript. Funding The authors received no specific funding for this work. Data availability All relevant data are within the manuscript and further data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Human Ethics and Consent to Participate declarations This study was approved by the Research Ethics Committee of Babol University of Medical Science, Babol, Iran (IR.MUBABOL.HRI.REC.1399.424). Our study adhered to the Declaration of Helsinki and the national guidelines. Eligible participants gave a written informed consent to participate in the study. Consent for publication Not applicable. Clinical trial number not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Ali Alizadeh Khatir, Email: alizade.ali83@yahoo.com. Ali Rostami, Email: alirostami1984@gmail.com. References Associated Data Data Availability Statement All relevant data are within the manuscript and further data that support the findings of this study are available from the corresponding author upon reasonable request.